Page 153 - Fluorescence-guided cancer surgery
P. 153
REFERENCES
12.
Patterson MS, Chance B, Wilson BC. Time resolved re ectance and transmittance for the non-invasive measurement of tissue optical properties. Appl Opt 1989;28:2331- 2336.
Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-128.
Monici M. Cell and tissue auto uorescence research and diagnostic applications. Biotechnol Annu Rev 2005;11:227-256.
van Dam GM, Themelis G, Crane LM et al. Intraoperative tumor-speci c uorescence imaging in ovarian cancer by folate receptor- alpha targeting: rst in-human results. Nat Med 2011;17:1315-1319.
Burggraaf J, Kamerling IM, Gordon PB et al. Detection of colorectal polyps in humans using an intravenously administered uorescent peptide targeted against c-Met. Nat Med 2015;21:955-961.
Tummers QR, Verbeek FP, Schaafsma BE et al. Real-time intraoperative detection of breast cancer using near-infrared uorescence imaging and Methylene Blue. Eur J Surg Oncol 2014;40:850-858.
Tummers QR, Hoogstins CE, Peters AA et al. The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer. PLoS One 2015;10:e0129766.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR e ect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284.
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387- 6392.
low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid- based receptor targeting for imaging and therapy of cancer and in ammatory diseases. Acc Chem Res 2008;41:120-129.
Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015.
1. Frangioni JV. In vivo near-infrared uorescence imaging. Curr Opin Chem Biol 2003;7:626-634.
13. 2. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-
589.
2730.
4. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:4059-4067.
5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence- guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
6. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006;367:1558-1560.
7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival e ect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248- 1259.
8. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-953.
9. Hoskins WJ, McGuire WP, Brady MF et al. The e ect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-979.
10. Handgraaf HJ, Verbeek FP, Tummers QR et al. Real-time near-infrared uorescence guided surgery in gynecologic oncology: a review of the current state of the art. Gynecol Oncol 2014;135:606-613.
11. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image- guided cancer surgery using near-infrared uorescence. Nat Rev Clin Oncol 2013;10:507- 518.
14. 3. Pleijhuis RG, Graa and M, de VJ, Bart J, de
jong JS, van Dam GM. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol 2009;16:2717-
Imaging FRĪ± positive ovarian and breast cancer 151
15.
16.
17.
18.
19.
20.
21.
22.
